

Article title: Cost-Effectiveness of Population Level and Individual Level Interventions to Combat Non-communicable Disease in Eastern Sub-Saharan Africa and South East Asia: A WHO-CHOICE Analysis

Journal name: International Journal of Health Policy and Management (IJHPM)

Authors' information: Melanie Y. Bertram^{1*}, Daniel Chisholm², Rory Watts¹, Temo Waqanivalu³, Vinayak Prasad³, Cherian Varghese⁴

¹Department of Health Systems Governance and Financing, World Health Organization, Geneva, Switzerland.

²Department of Mental Health and Substance Abuse, World Health Organization, Geneva, Switzerland.

³Department of Prevention of Non-Communicable Diseases, World Health Organization, Geneva, Switzerland.

⁴Department of Management of Non Communicable Diseases, Violence and Injury, World Health Organization, Geneva, Switzerland.

(*Corresponding author: bertramm@who.int)

Supplementary file 5. Cost, Impact and ACER Values for All Interventions

Intervention code	Coverage	Name	South East Asia			Eastern Sub-Saharan Africa		
			Cost per 10 million	HLY per 10 million (no disc)	ACER	Cost per 10 million	HLY per 10 million (no disc)	ACER
Cardiovascular Disease								
CVD-1	50	Prevention: Comb. Tx for total CVD risk > 30%, 50% coverage	\$265,229,707	9,039,000	\$29	\$504,982,376	19,044,395	\$27
CVD-2	50	Prevention: Tx SBP > 160 mmHG, total CVD risk < 30%, 50% coverage	\$281,056,741	1,598,781	\$176	\$540,172,822	6,384,497	\$85
CVD-3	50	Prevention: Tx SBP > 140 mmHG, total CVD risk < 30%, 50% coverage	\$181,292,781	3,445,038	\$53	\$381,881,749	7,642,586	\$50
CVD-4	50	Prevention: Tx Chol > 8mmol/L, total CVD risk < 30%, 50% coverage	\$51,509,752	26,783	\$1,923	\$169,326,999	4,289	\$39,476
CVD-5	50	Prevention: Tx Chol > 6mmol/L, total CVD risk < 30%, 50% coverage	\$403,631,938	2,397,396	\$168	\$724,262,599	1,620,356	\$447

CVD-6	50	Prevention: Comb. Tx for total CVD risk > 20%, 50% coverage	\$486,428,986	15,415,467	\$32	\$854,159,048	33,130,080	\$26
CVD-7	50	Prevention: Tx SBP > 160 mmHG, total CVD risk < 20%, 50% coverage	\$185,083,878	1,075,498	\$172	\$387,896,915	5,011,649	\$77
CVD-8	50	Prevention: Tx SBP > 140 mmHG, total CVD risk < 20%, 50% coverage	\$771,029,755	3,039,792	\$254	\$1,317,591,380	7,101,904	\$186
CVD-9	50	Prevention: Tx Chol > 8mmol/L, total CVD risk < 20%, 50% coverage	\$50,740,795	19,157	\$2,649	\$168,115,143	106,551	\$1,578
CVD-10	50	Prevention: Tx Chol > 6mmol/L, total CVD risk < 20%, 50% coverage	\$321,950,196	2,117,076	\$152	\$595,534,254	1,503,991	\$396
CVD-11	50	Treatment: Aspirin, 50% coverage	\$10,156,351	106,882	\$95	\$25,423,243	97,205	\$262
CVD-12	50	Treatment: Treat post acute IHD combination, 50% coverage	\$609,165,471	596,465	\$1,021	\$1,048,375,366	913,936	\$1,147
CVD-13	50	Treatment: Treat post acute Stroke combination, 50% coverage	\$565,589,900	544,109	\$1,039	\$935,620,079	657,824	\$1,422
CVD-14	80	Prevention: Comb. Tx for total CVD risk > 30%, 80% coverage	\$399,748,409	12,543,005	\$32	\$717,321,525	29,025,429	\$25
CVD-15	80	Prevention: Tx SBP > 160 mmHG, total CVD risk < 30%, 80% coverage	\$419,769,195	2,569,709	\$163	\$760,261,751	10,285,950	\$74
CVD-16	80	Prevention: Tx SBP > 140 mmHG, total CVD risk < 30%, 80% coverage	\$260,781,061	5,675,619	\$46	\$508,002,295	12,324,030	\$41
CVD-17	80	Prevention: Tx Chol > 8mmol/L, total CVD risk < 30%, 80% coverage	\$52,639,019	42,857	\$1,228	\$171,106,696	6,863	\$24,932
CVD-18	80	Tx Chol > 6mmol/L, total CVD risk < 30%, 80% coverage	\$618,088,725	3,683,730	\$168	\$1,062,241,034	2,598,182	\$409
CVD-19	80	Comb. Tx for total CVD risk > 20%, 80% coverage	\$765,489,465	19,914,191	\$38	\$1,294,707,754	41,750,500	\$31
CVD-20	80	Tx SBP > 160 mmHG, total CVD risk < 20%, 80% coverage	\$265,186,179	1,726,042	\$154	\$514,991,701	8,058,720	\$64
CVD-21	80	Tx SBP > 140 mmHG, total CVD risk < 20%, 80% coverage	\$1,208,247,262	4,896,924	\$247	\$2,011,305,106	11,442,499	\$176
CVD-22	80	Tx Chol > 8mmol/L, total CVD risk < 20%, 80% coverage	\$51,408,499	30,654	\$1,677	\$169,167,428	152,740	\$1,108
CVD-23	80	Tx Chol > 6mmol/L, total CVD risk < 20%, 80% coverage	\$486,816,276	3,248,968	\$150	\$855,358,997	2,410,987	\$355

CVD-24	80	Aspirin, 80% coverage	\$12,144,170	165,527	\$73	\$30,016,321	150,590	\$199
CVD-25	80	Treat post acute IHD combination, 80% coverage	\$989,283,022	1,004,451	\$985	\$1,649,151,246	1,597,520	\$1,032
CVD-26	80	Treat post acute Stroke combination, 80% coverage	\$872,464,097	1,011,651	\$862	\$1,389,889,834	1,165,001	\$1,193
CVD-27	95	Comb. Tx for total CVD risk > 30%, 95% coverage	\$467,545,191	13,915,963	\$34	\$824,339,440	31,339,161	\$26
CVD-28	95	Tx SBP > 160 mmHG, total CVD risk < 30%, 95% coverage	\$495,779,071	3,132,179	\$158	\$880,863,267	12,256,999	\$72
CVD-29	95	Tx SBP > 140 mmHG, total CVD risk < 30%, 95% coverage	\$300,806,241	6,625,521	\$45	\$571,508,482	14,692,383	\$39
CVD-30	95	Tx Chol > 8mmol/L, total CVD risk < 30%, 95% coverage	\$53,203,740	50,895	\$1,045	\$171,996,681	8,150	\$21,104
CVD-31	95	Tx Chol > 6mmol/L, total CVD risk < 30%, 95% coverage	\$725,679,448	4,042,845	\$179	\$1,231,801,274	3,088,687	\$399
CVD-32	95	Comb. Tx for total CVD risk > 20%, 95% coverage	\$905,067,222	21,762,893	\$42	\$1,515,057,123	44,905,380	\$34
CVD-33	95	Tx SBP > 160 mmHG, total CVD risk < 20%, 95% coverage	\$305,427,904	2,052,804	\$149	\$578,841,470	9,593,697	\$60
CVD-34	95	Tx SBP > 140 mmHG, total CVD risk < 20%, 95% coverage	\$1,428,642,973	5,835,032	\$245	\$2,360,997,254	13,635,625	\$173
CVD-35	95	Tx Chol > 8mmol/L, total CVD risk < 20%, 95% coverage	\$51,742,385	36,403	\$1,421	\$169,693,623	197,416	\$860
CVD-36	95	Tx Chol > 6mmol/L, total CVD risk < 20%, 95% coverage	\$569,432,231	3,671,065	\$155	\$985,559,639	2,865,831	\$344
CVD-37	95	Aspirin, 95% coverage	\$12,865,587	173,574	\$74	\$32,313,063	175,840	\$184
CVD-38	95	Treat post acute IHD combination, 95% coverage	\$1,193,436,413	1,224,876	\$974	\$1,971,815,731	1,988,804	\$991
CVD-39	95	Treat post acute Stroke combination, 95% coverage	\$1,026,389,343	1,147,591	\$894	\$1,617,747,323	1,461,416	\$1,107
CVD-40	95	prevention - 20% risk plus 160mmHG	\$1,244,977,332	23,815,697	\$52	\$2,080,319,886	41,048,900	\$51
CVD-41	95	prevention - 20% risk plus 140 mmHg	\$2,368,192,401	27,597,925	\$86	\$3,862,475,670	47,567,975	\$81
CVD-42	95	prevention - 20% risk 8mmol/L	\$936,592,274	21,799,296	\$43	\$1,574,238,159	37,573,417	\$42
CVD-43	95	prevention - 20% risk + 6mmol/L	\$1,454,282,120	25,433,958	\$57	\$2,390,104,174	43,838,146	\$55
CVD-44	95	prevention- 20% risk + 8mmol/L+160mmHg	\$1,255,497,253	23,852,099	\$53	\$2,107,748,181	41,111,644	\$51
CVD-45	95	prevention- 20% risk + 6mmol/L+160mmHg	\$1,805,189,585	27,486,761	\$66	\$2,979,920,747	53,431,842	\$56
CVD-46	95	prevention- 20% risk + 6mmol/L+140mmHg	\$2,928,404,655	31,268,990	\$94	\$4,762,076,531	57,473,770	\$83

CVD-47	95	prevention package plus treat stroke	\$4,253,285,116	32,416,581	\$131	\$6,428,186,686	58,935,186	\$109
CVD-48	95	prevention package plus treat stroke plus treat ihd	\$4,623,489,723	33,641,457	\$137	\$7,455,878,755	60,923,990	\$122
CVD-49	95	prevention package plus treat stroke plus treat ihd plus aspirin	\$6,295,933,903	33,815,031	\$186	\$9,515,687,046	61,099,830	\$156
Diabetes Mellitus								
DM-1	50	Standard Glycemic control, 50% coverage	\$1,121,365,306	162,226	\$6,912	\$850,060,574	132,875	\$6,397
DM-2	50	Intensive Glycemic control, 50% coverage	\$943,176,721	87,511	\$10,778	\$748,447,962	69,631	\$10,749
DM-3	50	Retinopathy Screening + photocoagulation, 50% coverage	\$388,972,419	60,406	\$6,439	\$401,469,841	44,734	\$8,975
DM-4	50	Neuropathy screening and preventive foot care, 50% coverage	\$78,525,814	106,059	\$740	\$161,881,836	78,443	\$2,064
DM-5	50	Standard plus intensive glycemic control, 50% coverage	\$2,041,102,879	253,253	\$8,060	\$1,476,826,872	203,219	\$7,267
DM-6	50	standard GC plus retinopathy screening, 50% coverage	\$1,968,542,192	225,145	\$8,743	\$1,494,383,639	177,939	\$8,398
DM-7	50	standard GC plus neuropathy screening, 50% coverage	\$1,273,361,231	271,769	\$4,685	\$926,142,030	211,857	\$4,372
DM-8	50	intensive GC plus retinopathy screening, 50% coverage	\$1,725,523,389	150,673	\$11,452	\$1,347,317,769	114,663	\$11,750
DM-9	50	intensive GC plus neuropathy screening, 50% coverage	\$1,089,534,294	197,264	\$5,523	\$823,300,808	148,557	\$5,542
DM-10	80	Standard Glycemic control, 80% coverage	\$1,781,996,807	261,593	\$6,812	\$1,276,856,728	212,909	\$5,997
DM-11	80	Intensive Glycemic control, 80% coverage	\$1,490,212,583	140,586	\$10,600	\$1,108,541,999	110,460	\$10,036
DM-12	80	Retinopathy Screening + photocoagulation, 80% coverage	\$590,537,938	96,904	\$6,094	\$509,691,653	70,869	\$7,192
DM-13	80	Neuropathy screening and preventive foot care, 80% coverage	\$98,955,070	170,481	\$580	\$166,950,927	124,520	\$1,341
DM-14	80	Standard plus intensive glycemic control, 80% coverage	\$3,255,125,231	410,086	\$7,938	\$2,265,718,232	328,213	\$6,903
DM-15	80	standard GC plus retinopathy screening, 80% coverage	\$3,130,129,024	364,030	\$8,599	\$2,246,680,061	287,033	\$7,827
DM-16	80	standard GC plus neuropathy screening, 80% coverage	\$2,019,980,293	440,307	\$4,588	\$1,381,603,994	342,267	\$4,037
DM-17	80	intensive GC plus retinopathy screening, 80% coverage	\$2,731,269,471	242,709	\$11,253	\$2,001,974,515	184,414	\$10,856

DM-18	80	intensive GC plus neuropathy screening, 80% coverage	\$1,718,270,594	318,402	\$5,397	\$1,210,484,636	239,292	\$5,059
DM-19	95	Standard Glycemic control, 95% coverage	\$2,115,845,320	311,861	\$6,785	\$1,492,663,488	253,611	\$5,886
DM-20	95	Intensive Glycemic control, 95% coverage	\$1,765,246,700	167,286	\$10,552	\$1,290,834,202	131,378	\$9,825
DM-21	95	Retinopathy Screening + photocoagulation, 95% coverage	\$692,400,936	115,225	\$6,009	\$564,402,850	84,241	\$6,700
DM-22	95	Neuropathy screening and preventive foot care, 95% coverage	\$109,233,939	202,916	\$538	\$169,517,246	148,129	\$1,144
DM-23	95	Standard plus intensive glycemic control, 95% coverage	\$3,867,202,969	489,923	\$7,893	\$2,664,830,255	391,596	\$6,805
DM-24	95	standard GC plus retinopathy screening, 95% coverage	\$3,717,136,445	434,572	\$8,554	\$2,627,063,485	342,252	\$7,676
DM-25	95	standard GC plus neuropathy screening, 95% coverage	\$2,397,237,404	526,170	\$4,556	\$1,611,908,604	408,427	\$3,947
DM-26	95	intensive GC plus retinopathy screening, 95% coverage	\$3,237,451,650	289,195	\$11,195	\$2,333,310,197	219,561	\$10,627
DM-27	95	intensive GC plus neuropathy screening, 95% coverage	\$2,034,388,993	379,772	\$5,357	\$1,406,490,807	285,118	\$4,933
Asthma								
AST-1	50	Inhaled short acting beta agonist for intermittent asthma, 50% coverage	\$10,452,854	2,663	\$3,926	\$26,069,059	11,677	\$2,232
AST-2	50	Low dose inhaled beclometasone + SABA, 50% coverage	\$20,750,654	44,216	\$469	\$27,383,991	193,917	\$141
AST-3	50	High dose inhaled beclometasone +SABA, 50% coverage	\$19,948,358	56,145	\$355	\$27,320,598	246,230	\$111
AST-4	50	Theophylline + High dose inhaled beclometasone +SABA, 50% coverage	\$11,399,232	50,214	\$227	\$26,965,313	220,222	\$122
AST-5	50	Oral Prednisolone + Theophylline + High dose inhaled beclometasone +SABA, 50% coverage	\$22,255,171	77,401	\$288	\$30,307,804	339,455	\$89
AST-6	80	Inhaled short acting beta agonist for intermittent asthma, 50% coverage	\$13,294,744	4,260	\$3,121	\$31,048,809	18,684	\$1,662
AST-7	80	Low dose inhaled beclometasone + SABA, 80% coverage	\$28,765,939	70,746	\$407	\$33,152,701	310,268	\$107

AST-8	80	High dose inhaled beclometasone +SABA, 80% coverage	\$27,482,266	89,831	\$306	\$33,051,273	393,969	\$84
AST-9	80	Theophylline + High dose inhaled beclometasone +SABA, 80% coverage	\$15,342,304	80,343	\$191	\$32,482,815	352,355	\$92
AST-10	80	Oral Prednisolone + Theophylline + High dose inhaled beclometasone +SABA, 80% coverage	\$32,746,311	123,842	\$264	\$37,830,801	543,128	\$70
AST-11	95	Inhaled short acting beta agonist for intermittent asthma, 95% coverage	\$14,715,689	5,059	\$2,909	\$33,538,684	22,187	\$1,512
AST-12	95	Low dose inhaled beclometasone + SABA, 95% coverage	\$32,773,582	84,011	\$390	\$36,037,056	368,443	\$98
AST-13	95	High dose inhaled beclometasone +SABA, 95% coverage	\$31,249,219	106,675	\$293	\$35,916,610	467,838	\$77
AST-14	95	Theophylline + High dose inhaled beclometasone +SABA, 95% coverage	\$17,313,841	95,407	\$181	\$35,241,567	418,421	\$84
AST-15	95	Oral Prednisolone + Theophylline + High dose inhaled beclometasone +SABA, 95% coverage	\$37,991,881	147,063	\$258	\$41,592,299	644,965	\$64
COPD								
COP-1	50	Smoking cessation, 50% coverage	\$75,840,651	552,424	\$137	\$278,136,851	1,066,922	\$261
COP-2	50	Inhaled salbutamol, 50% coverage	\$261,264,309	1,190,912	\$219	\$484,599,508	3,447,415	\$141
COP-3	50	Low-dose oral theophylline, 50% coverage	\$187,895,877	442,615	\$425	\$368,198,540	1,286,991	\$286
COP-4	50	Ipratropium inhaler, 50% coverage	\$252,893,070	384,124	\$658	\$472,169,552	1,111,126	\$425
COP-5	50	Antibiotics, 50% coverage	\$133,089,967	329,740	\$404	\$408,215,253	446,992	\$913
COP-6	50	Oral prednisolone, 50% coverage	\$110,327,936	326,650	\$338	\$349,527,204	945,577	\$370
COP-7	50	Oxygen, concentration 24-28%, 50% coverage	\$158,423,330	621,307	\$255	\$46,558,973	1,505,191	\$31
COP-8	50	Salbutamol plus theophylline, 50% coverage	\$405,189,655	1,636,224	\$248	\$716,356,821	4,734,444	\$151
COP-9	50	Salbutamol plus theophylline plus inpratropium, 50% coverage	\$628,394,521	2,020,348	\$311	\$1,073,095,363	5,845,570	\$184
COP-10	50	Antibiotics plus prednisolone plus oxygen, 50% coverage	\$1,706,318,465	1,287,225	\$1,326	\$804,301,430	2,652,683	\$303

COP-11	80	Smoking cessation, 80% coverage	\$80,837,974	887,715	\$91	\$310,314,586	1,695,317	\$183
COP-12	80	Inhaled salbutamol, 80% coverage	\$386,170,122	1,905,756	\$203	\$694,526,896	5,504,677	\$126
COP-13	80	Low-dose oral theophylline, 80% coverage	\$269,572,623	708,508	\$380	\$509,982,278	2,054,988	\$248
COP-14	80	Ipratropium inhaler, 80% coverage	\$375,383,344	613,682	\$612	\$679,886,296	1,777,802	\$382
COP-15	80	Antibiotics, 80% coverage	\$166,385,307	530,459	\$314	\$500,460,905	704,547	\$710
COP-16	80	Oral prednisolone, 80% coverage	\$130,216,116	522,640	\$249	\$412,365,877	1,509,854	\$273
COP-17	80	Oxygen, concentration 24-28%, 80% coverage	\$249,015,073	996,188	\$250	\$63,811,361	2,399,275	\$27
COP-18	80	Salbutamol plus theophylline, 80% coverage	\$610,453,374	2,617,958	\$233	\$1,052,964,247	7,575,110	\$139
COP-19	80	Salbutamol plus theophylline plus inpratropium, 80% coverage	\$961,931,341	3,232,556	\$298	\$1,611,919,357	9,352,913	\$172
COP-20	80	Antibiotics plus prednisolone plus oxygen, 80% coverage	\$2,604,411,376	2,071,745	\$1,257	\$976,638,144	4,222,763	\$231
COP-21	95	Smoking cessation, 95% coverage	\$80,905,209	1,057,007	\$77	\$321,325,179	2,015,998	\$159
COP-22	95	Inhaled salbutamol, 95% coverage	\$446,907,485	2,263,086	\$197	\$796,734,339	6,536,804	\$122
COP-23	95	Low-dose oral theophylline, 95% coverage	\$308,673,524	841,108	\$367	\$578,079,260	2,440,299	\$237
COP-24	95	Ipratropium inhaler, 95% coverage	\$434,873,023	728,748	\$597	\$780,895,160	2,111,140	\$370
COP-25	95	Antibiotics, 95% coverage	\$180,292,966	631,646	\$285	\$540,938,232	838,371	\$645
COP-26	95	Oral prednisolone, 95% coverage	\$137,403,588	620,732	\$221	\$438,290,448	1,792,952	\$244
COP-27	95	Oxygen, concentration 24-28%, 95% coverage	\$294,434,148	1,184,695	\$249	\$72,461,842	2,851,059	\$25
COP-28	95	Salbutamol plus theophylline, 95% coverage	\$711,023,830	3,108,825	\$229	\$1,217,966,473	8,995,444	\$135
COP-29	95	Salbutamol plus theophylline plus inpratropium, 95% coverage	\$1,126,183,899	3,838,661	\$293	\$1,877,313,444	11,106,584	\$169
COP-30	95	Antibiotics plus prednisolone plus oxygen, 95% coverage	\$634,887,004	2,467,552	\$257	\$1,051,690,522	5,017,981	\$210
Anxiety								
ANX-1	50	Basic psychosocial treatment for mild cases of anxiety disorder	\$247,108,300	166,339	\$1,486	\$424,348,592	436,738	\$972
ANX-2	50	Basic psychosocial and anti-depressant drug treatment for moderate-severe cases of anxiety disorder	\$267,669,821	165,748	\$1,615	\$426,853,199	458,476	\$931

ANX-3	50	Intensive psychosocial and anti-depressant drug treatment for moderate-severe cases of anxiety disorder	\$501,104,158	208,307	\$2,406	\$592,104,041	591,536	\$1,001
Depression								
DEP-1	50	Basic psychosocial treatment for mild cases of depression	\$326,958,789	664,717	\$492	\$448,801,495	1,700,970	\$264
DEP-2	50	Basic psychosocial treatment and anti-depressant medication for first-episode moderate-severe cases of depression	\$167,609,365	434,860	\$385	\$284,765,188	1,114,547	\$255
DEP-3	50	Intensive psychosocial treatment and anti-depressant medication for first-episode moderate-severe cases of depression	\$291,720,721	548,131	\$532	\$353,683,218	1,412,495	\$250
DEP-4	50	Intensive psychosocial treatment and anti-depressant medication for recurrent moderate-severe cases of depression on an episodic basis	\$574,472,702	1,252,653	\$459	\$549,751,103	3,229,200	\$170
DEP-5	50	Intensive psychosocial treatment and anti-depressant medication for recurrent moderate-severe cases of depression on a maintenance basis	\$660,822,502	2,234,969	\$296	\$634,697,669	5,694,731	\$111
Bipolar Disorder								
BIP-1	50	Mood-Stabilizing Medication + Basic Psychosocial treatment for bipolar disorder (older drugs)						
BIP-2	50	Mood-Stabilizing Medication + Intensive Psychosocial treatment for bipolar disorder (older drugs)						
BIP-3	50	Mood-Stabilizing Medication + Basic Psychosocial treatment for bipolar disorder (newer drugs)						
BIP-4	50	Mood-Stabilizing Medication + Intensive Psychosocial treatment for bipolar disorder (newer drugs)						
BIP-5	80	Mood-Stabilizing Medication + Basic Psychosocial treatment for bipolar disorder (older drugs)	\$767,621,808	511,304	\$1,501	\$985,331,403	1,130,380	\$872
BIP-6	80	Mood-Stabilizing Medication + Intensive Psychosocial treatment for bipolar disorder (older drugs)	\$1,214,691,346	596,521	\$2,036	\$1,169,053,899	1,318,776	\$886
BIP-7	80	Mood-Stabilizing Medication + Basic Psychosocial treatment for bipolar disorder (newer drugs)	\$1,188,048,038	511,304	\$2,324	\$1,594,178,590	1,130,380	\$1,410

BIP-8	80	Mood-Stabilizing Medication + Intensive Psychosocial treatment for bipolar disorder (newer drugs)	\$1,647,046,244	596,521	\$2,761	\$1,783,399,745	1,318,776	\$1,352
BIP-9	95	Mood-Stabilizing Medication + Basic Psychosocial treatment for bipolar disorder (older drugs)	\$903,882,378	607,174	\$1,489	\$1,139,888,502	1,342,326	\$849
BIP-10	95	Mood-Stabilizing Medication + Intensive Psychosocial treatment for bipolar disorder (older drugs)	\$1,434,777,455	708,369	\$2,025	\$1,358,058,966	1,566,047	\$867
BIP-11	95	Mood-Stabilizing Medication + Basic Psychosocial treatment for bipolar disorder (newer drugs)	\$1,403,138,526	607,174	\$2,311	\$1,862,894,537	1,342,326	\$1,388
BIP-12	95	Mood-Stabilizing Medication + Intensive Psychosocial treatment for bipolar disorder (newer drugs)	\$1,948,142,951	708,369	\$2,750	\$2,087,501,280	1,566,047	\$1,333
Psychosis								
PSY-1	50	AntiPsychotic Medication + Basic Psychosocial treatment of psychosis (older drugs)	\$275,439,477	248,176	\$1,110	\$393,248,399	463,092	\$849
PSY-2	50	AntiPsychotic Medication + Intensive Psychosocial treatment of psychosis (older drugs)	\$314,318,864	421,899	\$745	\$386,643,974	787,256	\$491
PSY-3	50	AntiPsychotic Medication + Basic Psychosocial treatment of psychosis (newer drugs)	\$294,827,241	248,176	\$1,188	\$416,706,903	463,092	\$900
PSY-4	50	AntiPsychotic Medication + Intensive Psychosocial treatment of psychosis (newer drugs)	\$334,187,793	421,899	\$792	\$410,540,276	787,256	\$521
PSY-5	80	AntiPsychotic Medication + Basic Psychosocial treatment of psychosis (older drugs)	\$414,685,934	397,081	\$1,044	\$532,274,598	740,947	\$718
PSY-6	80	AntiPsychotic Medication + Intensive Psychosocial treatment of psychosis (older drugs)	\$478,906,130	675,039	\$709	\$518,518,216	1,259,610	\$412
PSY-7	80	AntiPsychotic Medication + Basic Psychosocial treatment of psychosis (newer drugs)	\$445,598,112	397,081	\$1,122	\$569,808,205	740,947	\$769
PSY-8	80	AntiPsychotic Medication + Intensive Psychosocial treatment of psychosis (newer drugs)	\$510,807,736	675,039	\$757	\$556,527,565	1,259,610	\$442
PSY-9	95	AntiPsychotic Medication + Basic Psychosocial treatment of psychosis (older drugs)						

PSY-10	95	AntiPsychotic Medication + Intensive Psychosocial treatment of psychosis (older drugs)						
PSY-11	95	AntiPsychotic Medication + Basic Psychosocial treatment of psychosis (newer drugs)						
PSY-12	95	AntiPsychotic Medication + Intensive Psychosocial treatment of psychosis (newer drugs)						
Epilepsy								
EPI-1	50	AntiEpileptic Medication + Basic Psychosocial treatment of epilepsy (older drugs)	\$125,319,290	1,132,332	\$111	\$230,568,993	3,038,777	\$76
EPI-2	50	AntiEpileptic Medication + Basic Psychosocial treatment of epilepsy (newer drugs)	\$152,541,478	1,132,332	\$135	\$293,262,649	3,038,777	\$97
EPI-3	80	AntiEpileptic Medication + Basic Psychosocial treatment of epilepsy (older drugs)	\$164,273,558	1,644,673	\$100	\$264,672,731	4,544,746	\$58
EPI-4	80	AntiEpileptic Medication + Basic Psychosocial treatment of epilepsy (newer drugs)	\$204,028,333	1,644,673	\$124	\$358,740,667	4,544,746	\$79
EPI-5	95	AntiEpileptic Medication + Basic Psychosocial treatment of epilepsy (older drugs)						
EPI-6	95	AntiEpileptic Medication + Basic Psychosocial treatment of epilepsy (newer drugs)						
Risk Factor Prevention								
PA-1		Brief Intervention - Physical Activity	\$65,588,146	273,571	\$240	\$29,389,639	396,742	\$74
UD-1		Adopt interpretive front-of-pack nutrient labelling systems	\$14,200,394	3,235,397	\$4	\$42,251,147	6,890,161	\$6
UD-2		Set target levels for the amount of salt in food and implement strategies to promote reformulation	\$470,988	2,077,102	\$0	\$1,474,691	4,358,992	\$0
UD-3		Implement multicomponent salt reduction strategies in community settings including schools, workplaces and hospitals	\$4,246,565	804,444	\$5	\$17,194,933	955,082	\$18
UD-4		Complete Elimination of Industrial Transfats	\$148,541,225	25,398	\$5,849	\$186,877,181	36,108	\$5,176
TOB-1		Protect - Smoke Free Policies	\$14,200,394	252,101	\$56	\$9,792,328	741,132	\$13
TOB-2		Offer to Help Quit (Brief Intervention) Tobacco	\$65,588,146	125,948	\$521	\$29,389,639	370,302	\$79
TOB -3		Warning Labels Tobacco	\$6,678,474	252,101	\$26	\$4,384,947	741,132	\$6

TOB-4		Enforce Advertising Bans Tobacco	\$7,086,916	631,802	\$11	\$5,021,851	1,856,812	\$3
TOB-5		Raise Taxes Tobacco	\$5,400,016	13,460,010	\$0	\$4,908,197	34,757,605	\$0
Cancers		0						
CVC-1		Basic palliative care for Cervical cancer: home-based and hospital care with multi-disciplinary team and access to opiates and essential supportive medicines	\$211,330,021	2,769	\$76,313	\$155,645,256	25,520	\$6,099
CVC-2		Basic palliative care for Cervical cancer: home-based and hospital care with multi-disciplinary team and access to opiates and essential supportive medicines	\$234,013,422	4,431	\$52,815	\$192,347,733	40,832	\$4,711
CVC-3		Basic palliative care for Cervical cancer: home-based and hospital care with multi-disciplinary team and access to opiates and essential supportive medicines	\$245,355,123	5,262	\$46,632	\$169,911,240	48,488	\$3,504
CVC-4		Diagnosis & treatment of cervical cancer stages I and II (using surgery, radiotherapy and chemotherapy as needed)	\$197,825,685	171,314	\$1,155	\$173,358,489	918,353	\$189
CVC-5		Diagnosis & treatment of cervical cancer stages I and II (using surgery, radiotherapy and chemotherapy as needed)	\$220,224,197	335,061	\$657	\$223,364,806	1,777,983	\$126
CVC-6		Diagnosis & treatment of cervical cancer stages I and II (using surgery, radiotherapy and chemotherapy as needed)	\$231,423,452	445,670	\$519	\$460,559,737	2,355,450	\$196
CVC-7		HPV vaccination (2 doses) for preventing cervical cancer	\$232,111,233	1,112,285	\$209	\$286,113,995	5,215,136	\$55
CVC-8		HPV vaccination (2 doses) for preventing cervical cancer	\$262,249,565	1,499,743	\$175	\$373,016,469	6,773,262	\$55
CVC-9		HPV vaccination (2 doses) for preventing cervical cancer	\$277,318,731	1,630,353	\$170	\$233,063,199	7,297,912	\$32
CVC-10		HPV vaccination (2 doses) for preventing cervical cancer & Prevention of cervical cancer through screening with HPV test: women 30-49 yrs every 3 years linked with timely treatment of pre-cancerous lesions	\$429,588,735	4,284,936	\$100	\$763,994,050	24,649,274	\$31

CVC-11		HPV vaccination (2 doses) for preventing cervical cancer & Prevention of cervical cancer through screening with HPV test: women 30-49 yrs every 3 years linked with timely treatment of pre-cancerous lesions	\$576,910,674	4,927,198	\$117	\$1,143,584,301	29,121,530	\$39
CVC-12		HPV vaccination (2 doses) for preventing cervical cancer & Prevention of cervical cancer through screening with HPV test: women 30-49 yrs every 3 years linked with timely treatment of pre-cancerous lesions	\$650,237,299	5,109,215	\$127	\$1,567,691,503	30,413,350	\$52
CVC-13		HPV vaccination (2 doses) for preventing cervical cancer & Prevention of cervical cancer through screening with PAP: women 30-49 yrs every 3 years linked with timely treatment of pre-cancerous lesions	\$724,071,165	4,472,666	\$162	\$1,384,388,264	25,894,136	\$53
CVC-14		HPV vaccination (2 doses) for preventing cervical cancer & Prevention of cervical cancer through screening with PAP: women 30-49 yrs every 3 years linked with timely treatment of pre-cancerous lesions	\$1,028,175,176	5,059,125	\$203	\$2,118,330,191	30,073,810	\$70
CVC-15		HPV vaccination (2 doses) for preventing cervical cancer & Prevention of cervical cancer through screening with PAP: women 30-49 yrs every 3 years linked with timely treatment of pre-cancerous lesions	\$1,179,834,841	5,222,303	\$226	\$2,459,686,951	31,251,433	\$79
CVC-16		HPV vaccination (2 doses) for preventing cervical cancer & Prevention of cervical cancer through screening with VIA: women 30-49 yrs every 3 years linked with timely treatment of pre-cancerous lesions	\$547,369,903	4,541,842	\$121	\$978,065,571	26,362,292	\$37
CVC-17		HPV vaccination (2 doses) for preventing cervical cancer &	\$759,706,652	5,106,391	\$149	\$1,489,562,570	30,421,065	\$49

		Prevention of cervical cancer through screening with VIA: women 30-49 yrs every 3 years linked with timely treatment of pre-cancerous lesions						
CVC-18		HPV vaccination (2 doses) for preventing cervical cancer & Prevention of cervical cancer through screening with VIA: women 30-49 yrs every 3 years linked with timely treatment of pre-cancerous lesions	\$865,736,098	5,262,580	\$165	\$2,668,626,960	31,554,286	\$85
CVC-19		Prevention of cervical cancer through screening with HPV test: women 30-49 yrs every 3 years linked with timely treatment of pre-cancerous lesions	\$552,596,879	3,776,827	\$146	\$1,217,328,618	21,058,982	\$58
CVC-20		Prevention of cervical cancer through screening with HPV test: women 30-49 yrs every 3 years linked with timely treatment of pre-cancerous lesions	\$744,126,041	4,384,869	\$170	\$1,801,182,813	25,096,943	\$72
CVC-21		Prevention of cervical cancer through screening with HPV test: women 30-49 yrs every 3 years linked with timely treatment of pre-cancerous lesions	\$839,265,280	4,565,750	\$184	\$1,166,671,158	26,370,394	\$44
CVC-22		Prevention of cervical cancer through screening with PAP: women 30-49 yrs every 3 years linked with timely treatment of pre-cancerous lesions	\$583,174,470	4,002,315	\$146	\$1,091,493,251	22,516,816	\$48
CVC-23		Prevention of cervical cancer through screening with PAP: women 30-49 yrs every 3 years linked with timely treatment of pre-cancerous lesions	\$831,867,579	4,554,619	\$183	\$1,660,368,070	26,290,979	\$63
CVC-24		Prevention of cervical cancer through screening with PAP: women 30-49 yrs every 3 years linked with timely treatment of pre-cancerous lesions	\$955,726,092	4,714,860	\$203	\$2,285,793,684	27,447,414	\$83
CVC-25		Prevention of cervical cancer through screening with VIA:	\$512,420,812	4,085,368	\$125	\$888,388,618	23,064,846	\$39

		women 30-49 yrs every 3 years linked with timely treatment of pre-cancerous lesions						
CVC-26		Prevention of cervical cancer through screening with VIA: women 30-49 yrs every 3 years linked with timely treatment of pre-cancerous lesions	\$714,276,297	4,615,409	\$155	\$1,340,709,421	26,726,375	\$50
CVC-27		Prevention of cervical cancer through screening with VIA: women 30-49 yrs every 3 years linked with timely treatment of pre-cancerous lesions	\$814,928,544	4,767,951	\$171	\$1,845,726,367	27,901,962	\$66
CRC-1		Basic palliative care for Colorectal Cancer: home-based and hospital care with multi-disciplinary team and access to opiates and essential supportive medicines	\$212,692,708	3,128	\$67,986	\$122,483,474	2,949	\$41,540
CRC-2		Basic palliative care for Colorectal Cancer: home-based and hospital care with multi-disciplinary team and access to opiates and essential supportive medicines	\$236,193,722	5,006	\$47,186	\$139,288,883	4,718	\$29,525
CRC-3		Basic palliative care for Colorectal Cancer: home-based and hospital care with multi-disciplinary team and access to opiates and essential supportive medicines	\$247,944,229	5,944	\$41,713	\$147,691,587	5,602	\$26,363
CRC-4		Diagnosis & treatment of colorectal cancer stages I and II (with surgery, chemotherapy and radiotherapy as needed)	\$317,755,979	310,289	\$1,024	\$238,702,827	233,095	\$1,024
CRC-5		Diagnosis & treatment of colorectal cancer stages I and II (with surgery, chemotherapy and radiotherapy as needed)	\$357,459,009	633,637	\$564	\$272,958,560	464,692	\$587
CRC-6		Diagnosis & treatment of colorectal cancer stages I and II (with surgery, chemotherapy and radiotherapy as needed)	\$377,310,524	870,417	\$433	\$290,086,427	626,379	\$463

BRC-1		Basic palliative care for Breast Cancer: home-based and hospital care with multi-disciplinary team and access to opiates and essential supportive medicines	\$241,616,078	12,041	\$20,067	\$162,516,857	29,868	\$5,441
BRC-2		Basic palliative care for Breast Cancer: home-based and hospital care with multi-disciplinary team and access to opiates and essential supportive medicines	\$282,471,113	19,265	\$14,662	\$203,342,296	47,789	\$4,255
BRC-3		Basic palliative care for Breast Cancer: home-based and hospital care with multi-disciplinary team and access to opiates and essential supportive medicines	\$302,898,631	22,877	\$13,240	\$223,755,015	56,749	\$3,943
BRC-4		Diagnosis & treatment of breast cancer stages I and II (with surgery, radiotherapy and chemotherapy and hormone therapy as needed)	\$327,146,264	335,651	\$975	\$273,470,721	584,274	\$468
BRC-5		Diagnosis & treatment of breast cancer stages I and II (with surgery, radiotherapy and chemotherapy and hormone therapy as needed)	\$367,425,888	629,010	\$584	\$324,093,436	1,080,913	\$300
BRC-6		Diagnosis & treatment of breast cancer stages I and II (with surgery, radiotherapy and chemotherapy and hormone therapy as needed)	\$387,367,687	816,200	\$475	\$349,098,508	1,389,662	\$251
BRC-7		Screening with mammography (once in 2 years for the age group 50 to 69 years) linked with timely diagnosis and treatment	\$621,008,808	745,528	\$833	\$721,995,102	1,237,705	\$583
BRC-8		Screening with mammography (once in 2 years for the age group 50 to 69 years) linked with timely diagnosis and treatment	\$912,966,894	1,298,852	\$703	\$1,112,459,442	2,159,801	\$515
BRC-9		Screening with mammography (once in 2 years for the age group 50 to 69 years) linked with timely diagnosis and treatment	\$1,060,902,271	1,627,782	\$652	\$1,309,823,117	2,697,617	\$486